novartis
novartis'
not
newly
necessary
number
hits
has
had
have
hexal
hexal's
however
acquisition
acquisitions
acquired
announced
and
analysts
all
also
affiliate
after
able
about
as
adding
are
trail
trading
to
told
the
there
their
them
they
that
than
this
those
teva
swiss
sandoz
sal
sales
said
savings
shares
see
sell
strong
strange
statement
such
suffered
drug
drugmaker
drugmakers
drugs
deal
departments
development
do
565bn
5785
euros
eon
each
early
estimated
expected
expensive
expires
exactly
$74bn
$31
$200m
$5bn
Â£39bn
of
offered
overtake
on
outlook
oppenheim
purchases
producer
producers
products
protection
predicted
pressure
price
pharmaceuticals
partially
patent
pay
make
maker
making
may
market
markets
month
more
merge
merged
it
its
in
initially
investment
is
israel's
identical
unit
us
usually
world's
worldwide
work
would
which
where
will
were
biggest
birgit
bought
buy
business
be
based
bank
branded
generic
generics
germany's
growth
last
labs
for
forecast
force
following
francs
fragmented
from
figures
firm
find
record
remaining
reductions
research
reuters
rose
rivals
2005
2004
677%
cost
company
compensate
copy
consolidation
convinced
cuts
create
chemically
cheaply
can
call
year
1%
150
job
jobs
very
kuhlhoff